Theradigm, Inc., a portfolio company of Toucan Capital Fund II, is developing cell-based therapies for treatment of the central nervous system (CNS) disorders. Two different types of cells (1) neural stem cells and (2) bone marrow stromal cells may be applied alone or in combination to constitute unique therapies. Theradigm has a substantial intellectual property base covering use of these cells in CNS applications.